PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
16139805-4	2005	METHODS: Hormonal (adrenocorticotropic hormone [ACTH], cortisol, prolactin [PRL]) and temperature responses after administration of flesinoxan, a highly potent and selective 5-HT1A receptor full agonist, were assessed in 40 inpatients with major depression, divided into two subgroups (20 suicide attempters and 20 nonattempters), compared with 20 normal control subjects matched for gender and age.	flesinoxan	132-142	5-hydroxytryptamine receptor 1A	Homo sapiens	174-189
15084431-6	2004	It is proposed that the activation by flesinoxan of postsynaptic 5-HT1A receptors located in the LDT could be responsible for the REMS suppression.	flesinoxan	38-48	5-hydroxytryptamine receptor 1A	Rattus norvegicus	65-71
15194449-3	2004	We tested mice four times with 1-week intervals with the same dose of the 5-HT(1A) receptor agonist flesinoxan (0-0.3-1.0-3.0 mg/kg s.c.) in three anxiety-related paradigms: light-dark exploration, open-field activity and stress-induced hyperthermia.	flesinoxan	100-110	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	74-91
15194450-5	2004	Mice were treated with the selective 5-HT(1A) receptor agonist flesinoxan (0-0.3-1.0-3.0 mg/kg s.c.) and tested in either the open-field activity test, the light-dark exploration test, or the stress-induced hyperthermia paradigm.	flesinoxan	63-73	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	37-54
15964603-4	2005	The relative order of efficacy for activation of GIRK current was 5-HT approximately F 13714 approximately L 694,247 approximately LY 228,729>flesinoxan approximately (+/-)8-OH-DPAT.	flesinoxan	145-155	potassium inwardly rectifying channel subfamily J member 3 L homeolog	Xenopus laevis	49-53
15906386-7	2005	We did not find any difference in striatal [11C]raclopride binding between conditions, even though flesinoxan lead to typical 5-HT1A receptor agonist side effects and produced elevation of growth hormone in five of the six subjects.	flesinoxan	99-109	5-hydroxytryptamine receptor 1A	Homo sapiens	126-141
14517177-8	2003	The 5-HT1A receptor agonist flesinoxan (10, 50, 100 and 150 microg kg-1) induced a dose-dependent relaxation of the canine proximal stomach (50+/-10, 230+/-51, 290+/-38 and 275+/-33 ml, respectively; n=9-11).	flesinoxan	28-38	5-hydroxytryptamine receptor 1A	Canis lupus familiaris	4-19
15013031-1	2004	RATIONALE: Flesinoxan is a highly potent and selective 5-HT1A agonist.	flesinoxan	11-21	5-hydroxytryptamine receptor 1A	Homo sapiens	55-61
15013031-2	2004	In a recent study, in normal volunteers, flesinoxan induced a significant and dose-dependent increase in adrenocorticotropic hormone (ACTH), cortisol, prolactin (PRL), growth hormone (GH) and a decrease in body temperature.	flesinoxan	41-51	proopiomelanocortin	Homo sapiens	105-132
15013031-2	2004	In a recent study, in normal volunteers, flesinoxan induced a significant and dose-dependent increase in adrenocorticotropic hormone (ACTH), cortisol, prolactin (PRL), growth hormone (GH) and a decrease in body temperature.	flesinoxan	41-51	prolactin	Homo sapiens	151-160
15013031-2	2004	In a recent study, in normal volunteers, flesinoxan induced a significant and dose-dependent increase in adrenocorticotropic hormone (ACTH), cortisol, prolactin (PRL), growth hormone (GH) and a decrease in body temperature.	flesinoxan	41-51	prolactin	Homo sapiens	162-165
15013031-2	2004	In a recent study, in normal volunteers, flesinoxan induced a significant and dose-dependent increase in adrenocorticotropic hormone (ACTH), cortisol, prolactin (PRL), growth hormone (GH) and a decrease in body temperature.	flesinoxan	41-51	growth hormone 1	Homo sapiens	168-182
14985704-2	2004	This study investigated 5-HT1A receptor occupancy by the 5-HT1A agonist drugs flesinoxan (a highly selective probe for the 5-HT1A receptor) and ziprasidone (a novel atypical antipsychotic drug).	flesinoxan	78-88	5-hydroxytryptamine receptor 1A	Homo sapiens	24-39
14985704-2	2004	This study investigated 5-HT1A receptor occupancy by the 5-HT1A agonist drugs flesinoxan (a highly selective probe for the 5-HT1A receptor) and ziprasidone (a novel atypical antipsychotic drug).	flesinoxan	78-88	5-hydroxytryptamine receptor 1A	Homo sapiens	24-30
15013031-8	2004	CONCLUSIONS: These results show the role of 5-HT1A mechanisms in the PRL, ACTH, GH, and temperature responses to flesinoxan, and the role of 5-HT2 mechanisms in PRL and ACTH responses.	flesinoxan	113-123	5-hydroxytryptamine receptor 1A	Homo sapiens	44-50
15013031-8	2004	CONCLUSIONS: These results show the role of 5-HT1A mechanisms in the PRL, ACTH, GH, and temperature responses to flesinoxan, and the role of 5-HT2 mechanisms in PRL and ACTH responses.	flesinoxan	113-123	prolactin	Homo sapiens	69-72
14517177-9	2003	The selective 5-HT1A receptor antagonist WAY-100635 dose-dependently inhibited the flesinoxan-induced relaxation.	flesinoxan	83-93	5-hydroxytryptamine receptor 1A	Canis lupus familiaris	14-29
14517177-14	2003	It is concluded that flesinoxan induces proximal gastric relaxation in conscious dogs via 5-HT1A receptors.	flesinoxan	21-31	5-hydroxytryptamine receptor 1A	Canis lupus familiaris	90-96
12171388-3	2002	Therefore, we tested whether subjects with BPD showed a blunted prolactin (PRL) response to flesinoxan, a highly potent and selective 5-HT1A agonist.	flesinoxan	92-102	prolactin	Homo sapiens	64-73
12655311-0	2003	Modulation of passive avoidance in mice by the 5-HT1A receptor agonist flesinoxan: comparison with the benzodiazepine receptor agonist diazepam.	flesinoxan	71-81	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	47-62
12373416-0	2002	Hormonal and temperature responses to the 5-HT1A receptor agonist flesinoxan in normal volunteers.	flesinoxan	66-76	5-hydroxytryptamine receptor 1A	Homo sapiens	42-57
12373416-5	2002	RESULTS: Flesinoxan induced a significant and dose-dependent increase in adrenocorticotropic hormone (ACTH), cortisol, prolactin (PRL), growth hormone (GH) and a decrease in body temperature.	flesinoxan	9-19	proopiomelanocortin	Homo sapiens	73-100
12373416-5	2002	RESULTS: Flesinoxan induced a significant and dose-dependent increase in adrenocorticotropic hormone (ACTH), cortisol, prolactin (PRL), growth hormone (GH) and a decrease in body temperature.	flesinoxan	9-19	proopiomelanocortin	Homo sapiens	102-106
12373416-5	2002	RESULTS: Flesinoxan induced a significant and dose-dependent increase in adrenocorticotropic hormone (ACTH), cortisol, prolactin (PRL), growth hormone (GH) and a decrease in body temperature.	flesinoxan	9-19	prolactin	Homo sapiens	119-128
12373416-5	2002	RESULTS: Flesinoxan induced a significant and dose-dependent increase in adrenocorticotropic hormone (ACTH), cortisol, prolactin (PRL), growth hormone (GH) and a decrease in body temperature.	flesinoxan	9-19	prolactin	Homo sapiens	130-133
12373416-5	2002	RESULTS: Flesinoxan induced a significant and dose-dependent increase in adrenocorticotropic hormone (ACTH), cortisol, prolactin (PRL), growth hormone (GH) and a decrease in body temperature.	flesinoxan	9-19	growth hormone 1	Homo sapiens	136-150
12373416-5	2002	RESULTS: Flesinoxan induced a significant and dose-dependent increase in adrenocorticotropic hormone (ACTH), cortisol, prolactin (PRL), growth hormone (GH) and a decrease in body temperature.	flesinoxan	9-19	growth hormone 1	Homo sapiens	152-154
12373416-7	2002	CONCLUSIONS: These results showed the role of 5-HT(1A) mechanisms in the PRL, ACTH, cortisol, GH, and temperature responses to flesinoxan.	flesinoxan	127-137	prolactin	Homo sapiens	73-76
12373416-7	2002	CONCLUSIONS: These results showed the role of 5-HT(1A) mechanisms in the PRL, ACTH, cortisol, GH, and temperature responses to flesinoxan.	flesinoxan	127-137	proopiomelanocortin	Homo sapiens	78-82
12373416-7	2002	CONCLUSIONS: These results showed the role of 5-HT(1A) mechanisms in the PRL, ACTH, cortisol, GH, and temperature responses to flesinoxan.	flesinoxan	127-137	growth hormone 1	Homo sapiens	94-96
12225695-5	2002	Furthermore, the 5-HT(1A) receptor agonist flesinoxan dose-dependently antagonized SIH and stress-induced tachycardia in WT, but not in KO, mice.	flesinoxan	43-53	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	17-34
12183221-4	2002	METHODS: We assessed the hormonal (prolactin and cortisol) responses to flesinoxan (a highly potent and selective 5-HT1A agonist) in 12 male inpatients meeting DSM-IV criteria for alcohol dependence, 3 weeks after the last reported use of alcohol and antidepressants.	flesinoxan	72-82	5-hydroxytryptamine receptor 1A	Homo sapiens	114-120
12171388-3	2002	Therefore, we tested whether subjects with BPD showed a blunted prolactin (PRL) response to flesinoxan, a highly potent and selective 5-HT1A agonist.	flesinoxan	92-102	prolactin	Homo sapiens	75-78
12171388-8	2002	Among the BPD in-patients, PRL responses to flesinoxan were lower in patients with past history of suicide attempts (N = 8) than in those with a negative history.	flesinoxan	44-54	prolactin	Homo sapiens	27-30
11827741-4	2002	The effects of 5-HT(1A) receptor activation by flesinoxan (0.1-3.0 mg/kg s.c.) were determined telemetrically on body temperature and heart rate in 5-HT(1B) KO and wild-type (WT) mice.	flesinoxan	47-57	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	15-32
12166089-3	2002	(+/-)-pindolol and flesinoxan, a 5-HT1A receptor full agonist, significantly decreased the extracellular levels of 5-HT in the raphe and prefrontal cortex.	flesinoxan	19-29	5-hydroxytryptamine receptor 1A	Homo sapiens	33-48
12166089-4	2002	The 5-HT and other 5-HT1A receptor agonists, flesinoxan and 8-hydroxy-2- (di-n-propylamino)tetralon (8-OH-DPAT), significantly decreased the population excitatory postsynaptic potential (EPSP) in the CA3-CA1 excitatory synapse in a dose-dependent manner.	flesinoxan	45-55	5-hydroxytryptamine receptor 1A	Homo sapiens	19-34
12166089-4	2002	The 5-HT and other 5-HT1A receptor agonists, flesinoxan and 8-hydroxy-2- (di-n-propylamino)tetralon (8-OH-DPAT), significantly decreased the population excitatory postsynaptic potential (EPSP) in the CA3-CA1 excitatory synapse in a dose-dependent manner.	flesinoxan	45-55	carbonic anhydrase 3	Homo sapiens	200-207
11259482-2	2001	Local infusion of the 5-HT(1A) receptor agonist flesinoxan (0.3, 1, 3 microM) for 30 min into the amygdala maximally decreased 5-HT to 50% of basal level.	flesinoxan	48-58	5-hydroxytryptamine receptor 1A	Homo sapiens	22-39
11457654-0	2001	Active efflux of the 5-HT(1A) receptor agonist flesinoxan via P-glycoprotein at the blood-brain barrier.	flesinoxan	47-57	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	21-38
11457654-1	2001	The role of P-glycoprotein on the efflux of the 5-HT(1A) receptor agonist flesinoxan across the blood-brain barrier in vivo and in vitro was investigated.	flesinoxan	74-84	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	48-65
11457654-4	2001	In vivo, the accumulation of flesinoxan in the brain at 3 h was much higher in the mdr1a(-/-) mice compared to mdr1a(+/+) mice (ratio 12.6 and 27.0 at dose levels of 3 mg/kg and 10 mg/kg respectively).	flesinoxan	29-39	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	83-88
11457654-5	2001	In conclusion, both in vivo as well as in vitro results have demonstrated that Pgp is a limiting factor for the transport of the 5-HT(1A) receptor agonist flesinoxan into the CNS.	flesinoxan	155-165	phosphoglycolate phosphatase	Mus musculus	79-82
11457654-5	2001	In conclusion, both in vivo as well as in vitro results have demonstrated that Pgp is a limiting factor for the transport of the 5-HT(1A) receptor agonist flesinoxan into the CNS.	flesinoxan	155-165	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	129-146
11297713-3	2001	Moreover, on pharmacologic challenges with the 5-HT(1A) receptor agonist flesinoxan we expected an absence of the functional response in knockout mice relative to wild type mice.	flesinoxan	73-83	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	47-64
11297713-4	2001	METHODS: Effects of the 5-HT(1A) receptor agonist flesinoxan, alone or in combination with the 5-HT(1A) receptor antagonist WAY-100635, and the gamma-aminobutyric acid A (GABA(A))-benzodiazepine receptor agonist diazepam were studied in the SIH paradigm in male 129/Sv 5-HT(1A) receptor knockout and wild type mice.	flesinoxan	50-60	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	24-41
11259482-9	2001	Both the flesinoxan and WAY 100.635 data suggest an involvement of postsynaptic 5-HT(1A) receptor-mediated feedback in the amygdala, which diminishes following chronic citalopram treatment.	flesinoxan	9-19	5-hydroxytryptamine receptor 1A	Homo sapiens	80-97
11490174-5	2001	Dexamethasone nonsuppressors exhibited lower ACTH responses to flesinoxan as compared with dexamethasone suppressors.	flesinoxan	63-73	proopiomelanocortin	Homo sapiens	45-49
11243496-6	2001	In addition, corticosterone was measured 60 min after 5-HT1A receptor activation by flesinoxan (0, 0.03, 0.1, 0.3, 1, and 3 mg/kg s.c.).	flesinoxan	84-94	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	54-69
10980269-5	2000	We found that a single injection of flesinoxan (3 and 10 mg/kg subcutaneously, s.c.) after 3 h leads to a downregulation of glucocorticoid receptor mRNA in the hippocampus (dentate gyrus and CA1 areas) and dorsal raphe nucleus.	flesinoxan	36-46	nuclear receptor subfamily 3, group C, member 1	Rattus norvegicus	124-147
10980269-5	2000	We found that a single injection of flesinoxan (3 and 10 mg/kg subcutaneously, s.c.) after 3 h leads to a downregulation of glucocorticoid receptor mRNA in the hippocampus (dentate gyrus and CA1 areas) and dorsal raphe nucleus.	flesinoxan	36-46	carbonic anhydrase 1	Rattus norvegicus	191-194
10980269-8	2000	The decrease in hippocampal glucocorticoid receptor mRNA expression occurs independently of circulating corticosterone since flesinoxan reduced glucocorticoid receptor mRNA in the hippocampus of adrenalectomized rats with or without corticosterone replacement.	flesinoxan	125-135	nuclear receptor subfamily 3, group C, member 1	Rattus norvegicus	28-51
10980269-8	2000	The decrease in hippocampal glucocorticoid receptor mRNA expression occurs independently of circulating corticosterone since flesinoxan reduced glucocorticoid receptor mRNA in the hippocampus of adrenalectomized rats with or without corticosterone replacement.	flesinoxan	125-135	nuclear receptor subfamily 3, group C, member 1	Rattus norvegicus	144-167
10980269-9	2000	These data indicate that the 5-HT(1A) receptor agonist flesinoxan alters glucocorticoid receptor expression via a direct pathway independently of corticosterone and argues for an intrinsic effect selective for hippocampal glucocorticoid receptor mRNA.	flesinoxan	55-65	nuclear receptor subfamily 3, group C, member 1	Rattus norvegicus	73-96
10980269-9	2000	These data indicate that the 5-HT(1A) receptor agonist flesinoxan alters glucocorticoid receptor expression via a direct pathway independently of corticosterone and argues for an intrinsic effect selective for hippocampal glucocorticoid receptor mRNA.	flesinoxan	55-65	nuclear receptor subfamily 3, group C, member 1	Rattus norvegicus	222-245
10585418-11	1999	Spontaneous 5-HT1A receptor activity was partially attenuated by 5-HT1A receptor partial agonists with anxiolytic activity (e.g. buspirone and flesinoxan) but was not altered by full agonists or antagonists.	flesinoxan	143-153	5-hydroxytryptamine receptor 1A	Homo sapiens	65-80
10725568-2	2000	Therefore, the relationship between CNV and serotonergic activity as reflected by prolactin (PRL) response to flesinoxan, a 5-HT(1A) full agonist, has been investigated in 28 healthy volunteers.	flesinoxan	110-120	prolactin	Homo sapiens	82-91
11343599-1	2000	Previous drug discrimination studies with the 5-HT1 receptor agonists flesinoxan and eltoprazine showed a clear 5-HT1A receptor-mediated effect for flesinoxan and the involvement of both 5-HT1A and 5-HT1B receptors in eltoprazine.	flesinoxan	70-80	5-hydroxytryptamine receptor 1A	Rattus norvegicus	112-118
11343599-1	2000	Previous drug discrimination studies with the 5-HT1 receptor agonists flesinoxan and eltoprazine showed a clear 5-HT1A receptor-mediated effect for flesinoxan and the involvement of both 5-HT1A and 5-HT1B receptors in eltoprazine.	flesinoxan	148-158	5-hydroxytryptamine receptor 1A	Rattus norvegicus	112-118
11343599-3	2000	In the present experiments, in order to create a specific 5-HT1A vs. 5-HT1B receptor-mediated discrimination, rats were trained to discriminate between flesinoxan and eltoprazine.	flesinoxan	152-162	5-hydroxytryptamine receptor 1A	Rattus norvegicus	58-64
11343599-9	2000	The selective 5-HT1A receptor antagonist WAY-100635 antagonized the flesinoxan cue, and the discriminative stimulus of eltoprazine could be completely antagonized with the 5-HT1B/1D receptor antagonist GR-127935.	flesinoxan	68-78	5-hydroxytryptamine receptor 1A	Rattus norvegicus	14-20
11343599-11	2000	We conclude that rats can learn to discriminate between two serotonergic drugs with overlapping stimulus properties and that the flesinoxan stimulus is mediated by 5-HT1A receptors and the eltoprazine stimulus, under these particular training conditions, by 5-HT1B receptors.	flesinoxan	129-139	5-hydroxytryptamine receptor 1A	Rattus norvegicus	164-170
11343599-11	2000	We conclude that rats can learn to discriminate between two serotonergic drugs with overlapping stimulus properties and that the flesinoxan stimulus is mediated by 5-HT1A receptors and the eltoprazine stimulus, under these particular training conditions, by 5-HT1B receptors.	flesinoxan	129-139	5-hydroxytryptamine receptor 1B	Rattus norvegicus	258-264
10913585-3	2000	Flesinoxan, a selective 5-HT(1A) receptor agonist with anxiolytic-like properties, causes hypothermia, which complicates interpretation of stress-induced hyperthermia.	flesinoxan	0-10	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	24-41
10788764-6	2000	In experiments using intact 129Sv mice, the 5-HT(1A) agonist flesinoxan increased PPI while anpirtoline decreased PPI and habituation.	flesinoxan	61-71	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	44-51
10585418-11	1999	Spontaneous 5-HT1A receptor activity was partially attenuated by 5-HT1A receptor partial agonists with anxiolytic activity (e.g. buspirone and flesinoxan) but was not altered by full agonists or antagonists.	flesinoxan	143-153	5-hydroxytryptamine receptor 1A	Homo sapiens	12-27
10515319-5	1999	The 5-HT1A receptor antagonists DU125530 (0.5-13 mg/kg) and WAY100,635 (0.1-1 mg/kg) partially antagonized the generalization of mianserin to flesinoxan.	flesinoxan	142-152	5-hydroxytryptamine receptor 1A	Homo sapiens	4-19
10579422-4	1999	Twenty-three normal subjects answered the TPQ, and the serotonergic activity was assessed by the prolactin response to a highly potent and selective 5-HT1a agonist (flesinoxan).	flesinoxan	165-175	5-hydroxytryptamine receptor 1A	Homo sapiens	149-155
10515319-0	1999	The 5-HT1A receptor agonist flesinoxan shares discriminative stimulus properties with some 5-HT2 receptor antagonists.	flesinoxan	28-38	5-hydroxytryptamine receptor 1A	Homo sapiens	4-19
10572339-3	1999	The study was conducted among 45 major depressive inpatients, and serotonergic activity was assessed by prolactin (PRL) response to flesinoxan (a 5-HT1A agonist).	flesinoxan	132-142	5-hydroxytryptamine receptor 1A	Homo sapiens	146-152
10523050-0	1999	Effect of sustained administration of the 5-HT1A receptor agonist flesinoxan on rat 5-HT neurotransmission.	flesinoxan	66-76	5-hydroxytryptamine receptor 1A	Rattus norvegicus	42-48
10523050-7	1999	The marked potency and the long dissociation constant of flesinoxan for the 5-HT1A receptors may account for the latter discrepancy.	flesinoxan	57-67	5-hydroxytryptamine receptor 1A	Rattus norvegicus	76-82
10523050-8	1999	In conclusion, as for selective 5-HT re-uptake inhibitors, monoamine oxidase inhibitors and 5-HT1A receptor agonists, flesinoxan produced most of the adaptive changes exerted by these antidepressant drugs on the 5-HT system.	flesinoxan	118-128	5-hydroxytryptamine receptor 1A	Rattus norvegicus	92-98
10572339-4	1999	Results showed a significant negative correlation between P300 amplitude and PRL response to flesinoxan (r = -0.40, P = 0.007 at Cz; r = -0.47, P = 0.001 at Pz).	flesinoxan	93-103	E1A binding protein p300	Homo sapiens	58-62
9918598-4	1999	Systemic administration of selective 5-HT1A agonists, 8-hydroxy-2-(di-n-propylamino)tetralin, buspirone, ipsapirone, and flesinoxan produced a dose-dependent inhibition of neuronal activity.	flesinoxan	121-131	5-hydroxytryptamine receptor 1A	Rattus norvegicus	37-43
10530928-7	1999	Similarly, the selective serotonin 5-HT1A receptor agonist flesinoxan was employed for identifying the serotonin 5-HT1A receptor binding conformations of the enantiomers of 1.	flesinoxan	59-69	5-hydroxytryptamine receptor 1A	Homo sapiens	35-50
10530928-7	1999	Similarly, the selective serotonin 5-HT1A receptor agonist flesinoxan was employed for identifying the serotonin 5-HT1A receptor binding conformations of the enantiomers of 1.	flesinoxan	59-69	5-hydroxytryptamine receptor 1A	Homo sapiens	113-128
10475723-0	1999	The 5-HT1A receptor agonist flesinoxan increases aversion in a model of panic-like anxiety in rats.	flesinoxan	28-38	5-hydroxytryptamine receptor 1A	Homo sapiens	4-19
10475723-1	1999	Acute systemic administration of the selective serotonin (5-HT)1A receptor full agonist flesinoxan enhanced the sensitivity of rats to the panic-like aversion elicited by local stimulation of the dorsolateral periaqueductal grey (dPAG).	flesinoxan	88-98	5-hydroxytryptamine receptor 1A	Rattus norvegicus	47-74
9726650-0	1998	Flesinoxan treatment reduces 5-HT1A receptor mRNA in the dentate gyrus independently of high plasma corticosterone levels.	flesinoxan	0-10	5-hydroxytryptamine receptor 1A	Rattus norvegicus	29-35
9723787-1	1998	This study examined the influence of the highly selective 5-HT1A receptor ligands, flesinoxan, S 15535, and WAY 100,635, upon the electrical activity of dopaminergic neurons in the ventral tegmental area (VTA), as compared to serotonergic neurons in the dorsal raphe nucleus (DRN) of anesthetized rats.	flesinoxan	83-93	5-hydroxytryptamine receptor 1A	Rattus norvegicus	58-64
9723787-2	1998	Flesinoxan, a high-efficacy agonist at both pre- and postsynaptic 5-HT1A receptors, dose-dependently (inhibitory dose (ID)50 = 19.5 microg/kg, i.v.)	flesinoxan	0-10	5-hydroxytryptamine receptor 1A	Rattus norvegicus	66-72
9726650-1	1998	Flesinoxan acts as a full 5-HT1A receptor agonist and displays anxiolytic and anti-depressant properties.	flesinoxan	0-10	5-hydroxytryptamine receptor 1A	Rattus norvegicus	26-32
9726650-2	1998	5-HT1A receptor agonists, including flesinoxan, increase corticosterone (B) levels in the blood and reduces 5-HT1A receptor mRNA expression in the hippocampus.	flesinoxan	36-46	5-hydroxytryptamine receptor 1A	Rattus norvegicus	0-6
9726650-2	1998	5-HT1A receptor agonists, including flesinoxan, increase corticosterone (B) levels in the blood and reduces 5-HT1A receptor mRNA expression in the hippocampus.	flesinoxan	36-46	5-hydroxytryptamine receptor 1A	Rattus norvegicus	108-114
9726650-3	1998	In this study, we examined whether the 5-HT1A receptor downregulation induced by flesinoxan involves corticosterone control of 5-HT1A receptor gene transcription.	flesinoxan	81-91	5-hydroxytryptamine receptor 1A	Rattus norvegicus	39-45
9726650-3	1998	In this study, we examined whether the 5-HT1A receptor downregulation induced by flesinoxan involves corticosterone control of 5-HT1A receptor gene transcription.	flesinoxan	81-91	5-hydroxytryptamine receptor 1A	Rattus norvegicus	127-133
9726650-5	1998	Flesinoxan administration resulted in a significant, dose-dependent downregulation of 5-HT1A receptor mRNA in the dentate gyrus and dorsal raphe nucleus.	flesinoxan	0-10	5-hydroxytryptamine receptor 1A	Rattus norvegicus	86-92
9726650-7	1998	Flesinoxan injection also caused a dose-dependent decrease of 5-HT1A mRNA in the dentate gyrus of adrenalectomized animals with corticosterone replacement.	flesinoxan	0-10	5-hydroxytryptamine receptor 1A	Rattus norvegicus	62-68
9726650-9	1998	In experiment III, adrenalectomized and adrenalectomized + corticosterone rats were sc injected with flesinoxan (10 mg/kg bw) or vehicle, and flesinoxan appeared to downregulate 5-HT1A receptor expression in the dentate gyrus independently of corticosterone as well.	flesinoxan	142-152	5-hydroxytryptamine receptor 1A	Rattus norvegicus	178-184
9726650-11	1998	It is concluded that flesinoxan reduces 5-HT1A receptor expression in the dentate gyrus both through homologous downregulation and a corticosterone-mediated effect on the serotonergic (5-HT) system.	flesinoxan	21-31	5-hydroxytryptamine receptor 1A	Rattus norvegicus	40-46
9022796-0	1997	5-HT1A-versus D2-receptor selectivity of flesinoxan and analogous N4-substituted N1-arylpiperazines.	flesinoxan	41-51	5-hydroxytryptamine receptor 1A	Rattus norvegicus	0-6
9548383-0	1998	Anxiolytic effects of flesinoxan in the stress-induced hyperthermia paradigm in singly-housed mice are 5-HT1A receptor mediated.	flesinoxan	22-32	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	103-118
9548383-3	1998	The full 5-HT1A receptor agonist flesinoxan ((+)-enantiomer), its (-)-enantiomer and the racemic mixture reduced stress-induced hyperthermia effects, indicating putative anxiolytic properties.	flesinoxan	33-43	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	9-24
9314028-2	1997	Systemic administration of flesinoxan, a selective 5-HT1A receptor agonist, significantly reduced the extracellular levels of 5-HT in the central nucleus of the amygdala.	flesinoxan	27-37	5-hydroxytryptamine receptor 1A	Homo sapiens	51-66
9218690-7	1997	An inhibition of phosphoinositide hydrolysis in the dorsal raphe nucleus also was found with the putative 5-HT1A receptor selective ligands, flesinoxan and gepirone.	flesinoxan	141-151	5-hydroxytryptamine receptor 1A	Homo sapiens	106-121
9163558-6	1997	The anxiolytic effects of 8-OH-DPAT and flesinoxan could only be antagonized with a high dose (1.0 and 3.0 mg/kg respectively) of the 5-HT1A receptor antagonist WAY-100635 (N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl) cyclohexanecarboxamide trihydrochloride).	flesinoxan	40-50	5-hydroxytryptamine receptor 1A	Rattus norvegicus	134-140
9163561-0	1997	The putative 5-HT1A receptor antagonist DU125530 blocks the discriminative stimulus of the 5-HT1A receptor agonist flesinoxan in pigeons.	flesinoxan	115-125	5-hydroxytryptamine receptor 1A	Homo sapiens	13-28
9163561-0	1997	The putative 5-HT1A receptor antagonist DU125530 blocks the discriminative stimulus of the 5-HT1A receptor agonist flesinoxan in pigeons.	flesinoxan	115-125	5-hydroxytryptamine receptor 1A	Homo sapiens	91-106
9163561-3	1997	Tests for generalization and antagonism showed that compounds with agonistic action at the 5-HT1A receptor, such as 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin), buspirone and ipsapirone all substituted for the flesinoxan cue.	flesinoxan	217-227	5-hydroxytryptamine receptor 1A	Homo sapiens	91-106
9163561-11	1997	Taken together these results suggest that the flesinoxan cue in pigeons is mediated by the 5-HT1A receptor and that DU125530 acts as a full antagonist on the 5-HT1A receptor.	flesinoxan	46-56	5-hydroxytryptamine receptor 1A	Homo sapiens	91-106
9169298-2	1997	Flesinoxan is an example which is highly selective for the 5-HT1A receptor subtype.	flesinoxan	0-10	5-hydroxytryptamine receptor 1A	Rattus norvegicus	59-65
9169298-10	1997	These studies illustrate the potential antidepressant properties of flesinoxan, and hence further emphasise the role of the 5-HT1A receptor in the pathogenesis of depression.	flesinoxan	68-78	5-hydroxytryptamine receptor 1A	Rattus norvegicus	124-130
9181641-0	1997	Flesinoxan pretreatment differentially affects corticosterone, prolactin and behavioural responses to a flesinoxan challenge.	flesinoxan	0-10	prolactin	Rattus norvegicus	63-72
9181641-3	1997	Several 5-HT1A receptor mediated responses were modified differentially following the flesinoxan pretreatment.	flesinoxan	86-96	5-hydroxytryptamine receptor 1A	Rattus norvegicus	8-14
9181641-5	1997	The differential changes in the responses to flesinoxan cannot easily be explained by differences in pre- or postsynaptically 5-HT1A mediated responses.	flesinoxan	45-55	5-hydroxytryptamine receptor 1A	Rattus norvegicus	126-132
9181641-6	1997	The prolactin response to flesinoxan, which is thought to be mediated postsynaptically, was enhanced, whereas the corticosterone response to flesinoxan, which is also mediated postsynaptically, was attenuated.	flesinoxan	26-36	prolactin	Rattus norvegicus	4-13
9145767-0	1997	Pretreatment with 5-HT1A receptor agonist flesinoxan attenuates Fos protein in rat hypothalamus.	flesinoxan	42-52	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	64-67
9145767-3	1997	Male rats received two injections with either flesinoxan or vehicle within 24 h. Flesinoxan challenge enhanced Fos immunoreactivity in the paraventricular nucleus of the hypothalamus, the central amygdala, and the dorsolateral part of the bed nucleus of the stria terminalis and plasma corticosterone levels in the vehicle-pretreated rats.	flesinoxan	46-56	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	111-114
9145767-3	1997	Male rats received two injections with either flesinoxan or vehicle within 24 h. Flesinoxan challenge enhanced Fos immunoreactivity in the paraventricular nucleus of the hypothalamus, the central amygdala, and the dorsolateral part of the bed nucleus of the stria terminalis and plasma corticosterone levels in the vehicle-pretreated rats.	flesinoxan	81-91	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	111-114
9145767-4	1997	Flesinoxan pretreatment resulted in an attenuated response of plasma corticosterone levels and Fos-positive neurons in the paraventricular nucleus of the hypothalamus, but not in the central amygdala and the bed nucleus after a flesinoxan challenge.	flesinoxan	0-10	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	95-98
9650801-9	1998	5-HT1A receptor agonists, e.g. 8-OH-DPAT and flesinoxan and partial agonists, e.g. pindolol, buspirone and ipsapirone had low potency in this in vivo assay.	flesinoxan	45-55	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	0-15
9089665-4	1997	Systemic administration of the 5-HT1A receptor agonists 8-OH-DPAT and flesinoxan dose-dependently decreased 5-HT levels in the CeA.	flesinoxan	70-80	5-hydroxytryptamine receptor 1A	Rattus norvegicus	31-37
9089665-4	1997	Systemic administration of the 5-HT1A receptor agonists 8-OH-DPAT and flesinoxan dose-dependently decreased 5-HT levels in the CeA.	flesinoxan	70-80	carcinoembryonic antigen gene family 4	Rattus norvegicus	127-130
9089665-5	1997	The effect of 0.3 mg/kg of flesinoxan could be completely antagonized by systemic administration of 0.05 mg/kg WAY 100635, a 5-HT1A receptor antagonist.	flesinoxan	27-37	5-hydroxytryptamine receptor 1A	Rattus norvegicus	125-131
9022796-1	1997	We investigated the structural requirements for high 5-HT1A affinity of the agonist flesinoxan and its selectivity versus D2 receptors.	flesinoxan	84-94	5-hydroxytryptamine receptor 1A	Rattus norvegicus	53-59
9022796-7	1997	In contrast to the structure-affinity relationships (SARs) of the N4-substituents, selectivity for 5-HT1A versus D2 receptors was gained by the arylpiperazine substitution pattern of flesinoxan.	flesinoxan	183-193	5-hydroxytryptamine receptor 1A	Rattus norvegicus	99-105
9022796-10	1997	These results were used to dock flesinoxan (1) and two of its congeners (27 and 33) into a model of the 5-HT1A receptor that we previously reported.	flesinoxan	32-42	5-hydroxytryptamine receptor 1A	Rattus norvegicus	104-110
9022796-13	1997	These observations from the 3D model agree with the 5-HT1A SAR data and probably account for the selectivity of flesinoxan versus D2 receptors.	flesinoxan	112-122	5-hydroxytryptamine receptor 1A	Rattus norvegicus	52-58
8950098-0	1996	5-HT1A receptor agonist flesinoxan enhances Fos immunoreactivity in rat central amygdala, bed nucleus of the stria terminalis and hypothalamus.	flesinoxan	24-34	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	44-47
8950098-5	1996	However, in typically non-5HT1A receptor-containing brain areas Fos-ir is increased due to flesinoxan treatment, as in the paraventricular nucleus of the hypothalamus (PVN), the dorsolateral part of the bed nucleus of the stria terminalis (BNSTdl) and the central amygdala (CeA).	flesinoxan	91-101	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	64-67
8950098-6	1996	Flesinoxan-treated rats also exhibited higher plasma corticosterone levels than vehicle-treated animals, which suggests the involvement of corticotropin-releasing hormone (CRH) or vasopressin in the hypothalamus.	flesinoxan	0-10	corticotropin releasing hormone	Rattus norvegicus	139-170
8950098-6	1996	Flesinoxan-treated rats also exhibited higher plasma corticosterone levels than vehicle-treated animals, which suggests the involvement of corticotropin-releasing hormone (CRH) or vasopressin in the hypothalamus.	flesinoxan	0-10	corticotropin releasing hormone	Rattus norvegicus	172-175
8950098-6	1996	Flesinoxan-treated rats also exhibited higher plasma corticosterone levels than vehicle-treated animals, which suggests the involvement of corticotropin-releasing hormone (CRH) or vasopressin in the hypothalamus.	flesinoxan	0-10	arginine vasopressin	Rattus norvegicus	180-191
8950098-10	1996	Accordingly, flesinoxan exerts its activating effects on the HPA axis via CRH neurons in the PVN.	flesinoxan	13-23	corticotropin releasing hormone	Rattus norvegicus	74-77
8888384-0	1996	Effects of the 5-HT1A receptor agonist flesinoxan in panic disorder.	flesinoxan	39-49	5-hydroxytryptamine receptor 1A	Homo sapiens	15-30
8728565-1	1996	In the stress-induced hyperthermia (SIH) paradigm in mice, both a benzodiazepine receptor agonist, diazepam, and a 5-HT1A receptor agonist, flesinoxan, reduced the stress-induced increase in rectal temperature.	flesinoxan	140-150	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	115-130
8632181-0	1996	Flesinoxan dose-dependently reduces extracellular 5-hydroxytryptamine (5-HT) in rat median raphe and dorsal hippocampus through activation of 5-HT1A receptors.	flesinoxan	0-10	5-hydroxytryptamine receptor 1A	Rattus norvegicus	142-148
8632181-1	1996	The effects of systemic administration of the serotonin (5-hydroxytryptamine) 5-HT1A receptor agonists flesinoxan and 8-hydroxy-2-(di-n-propylamino)tetralin on extracellular 5-HT were measured using microdialysis probes in both median raphe nucleus and dorsal hippocampus.	flesinoxan	103-113	5-hydroxytryptamine receptor 1A	Rattus norvegicus	78-84
8632181-3	1996	The effects of flesinoxan in the median raphe (0.3 mg/kg) and dorsal hippocampus (1.0 mg/kg) could be blocked by the 5-HT1A receptor antagonist N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridyl)cyclohexane carboxamide trihydrochloride (WAY 100,635) at a dose of 0.05 mg/kg s.c.	flesinoxan	15-25	5-hydroxytryptamine receptor 1A	Rattus norvegicus	117-123
8632181-7	1996	The data indicate that flesinoxan is a potent 5-HT1A receptor agonist and also support the notion that somatodendritic 5-HT1A autoreceptors regulate both terminal and somatodendritic 5-HT release.	flesinoxan	23-33	5-hydroxytryptamine receptor 1A	Rattus norvegicus	46-52
8632181-7	1996	The data indicate that flesinoxan is a potent 5-HT1A receptor agonist and also support the notion that somatodendritic 5-HT1A autoreceptors regulate both terminal and somatodendritic 5-HT release.	flesinoxan	23-33	5-hydroxytryptamine receptor 1A	Rattus norvegicus	119-125
8788480-1	1996	In mice injected with formalin into the hindpaw, the 5-HT1A receptor agonists, 8-OH-DPAT and flesinoxan, equipotently inhibited the early phase (EP) and late phase (LP) of licking.	flesinoxan	93-103	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	53-68
8899812-0	1996	Differential effects of the 5-HT 1B/2C receptor agonist mCPP and the 5-HT1A agonist flesinoxan on hypothalamic neuropeptide Y in the rat: evidence that NPY may mediate serotonin"s effects on food intake.	flesinoxan	84-94	5-hydroxytryptamine receptor 1A	Rattus norvegicus	69-75
8899812-4	1996	Acute flesinoxan injection increased food intake and NPY levels in the PVN and ARC (p < 0.01).	flesinoxan	6-16	neuropeptide Y	Rattus norvegicus	53-56
8570029-0	1995	Characterization of 5-hydroxytryptamine1A properties of flesinoxan: in vivo electrophysiology and hypothermia study.	flesinoxan	56-66	5-hydroxytryptamine receptor 1A	Rattus norvegicus	20-41
8570029-1	1995	Flesinoxan is a high affinity and selective 5-hydroxytryptamine1A (5-HT1A) ligand which, unlike the 5-HT1A agonists of the azapirone class, does not generate 1-(2-pyrimidinyl)piperazine, an alpha 2-adrenoreceptor antagonist.	flesinoxan	0-10	5-hydroxytryptamine receptor 1A	Rattus norvegicus	44-65
8570029-1	1995	Flesinoxan is a high affinity and selective 5-hydroxytryptamine1A (5-HT1A) ligand which, unlike the 5-HT1A agonists of the azapirone class, does not generate 1-(2-pyrimidinyl)piperazine, an alpha 2-adrenoreceptor antagonist.	flesinoxan	0-10	5-hydroxytryptamine receptor 1A	Rattus norvegicus	67-73
8570029-1	1995	Flesinoxan is a high affinity and selective 5-hydroxytryptamine1A (5-HT1A) ligand which, unlike the 5-HT1A agonists of the azapirone class, does not generate 1-(2-pyrimidinyl)piperazine, an alpha 2-adrenoreceptor antagonist.	flesinoxan	0-10	5-hydroxytryptamine receptor 1A	Rattus norvegicus	100-106
8570029-2	1995	In view of potential antidepressant effects of flesinoxan, this study was undertaken to characterize its 5-HT1A properties in the rat brain using in vivo electrophysiology and hypothermia paradigms.	flesinoxan	47-57	5-hydroxytryptamine receptor 1A	Rattus norvegicus	105-111
8570029-3	1995	The suppressant effect of microiontophoretic applications of flesinoxan on the firing activity of CA3 pyramidal neurons was blocked by concomitant application of the 5-HT1A antagonist BMY 7378.	flesinoxan	61-71	carbonic anhydrase 3	Rattus norvegicus	98-101
8570029-3	1995	The suppressant effect of microiontophoretic applications of flesinoxan on the firing activity of CA3 pyramidal neurons was blocked by concomitant application of the 5-HT1A antagonist BMY 7378.	flesinoxan	61-71	5-hydroxytryptamine receptor 1A	Rattus norvegicus	166-172
8570029-4	1995	Compared to gepirone, the efficacy of flesinoxan to suppress the firing activity of CA3 pyramidal neurons was significantly greater.	flesinoxan	38-48	carbonic anhydrase 3	Rattus norvegicus	84-87
8570029-6	1995	The capacity of flesinoxan to antagonize the effect of 5-HT on CA3 pyramidal neurons was similar to that of 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT) and significantly greater than that of gepirone.	flesinoxan	16-26	carbonic anhydrase 3	Rattus norvegicus	63-66
8570029-7	1995	The intravenous administration of flesinoxan suppressed the firing activity of both CA3 pyramidal neurons and dorsal raphe 5-HT neurons.	flesinoxan	34-44	carbonic anhydrase 3	Rattus norvegicus	84-87
8570029-12	1995	The flesinoxan-induced hypothermia was significantly attenuated by prior administration of the non-selective 5-HT1A antagonist pindolol and the 5-HT1/2 antagonist methysergide.	flesinoxan	4-14	5-hydroxytryptamine receptor 1A	Rattus norvegicus	109-115
8570029-15	1995	The 5-HT1A properties of flesinoxan suggest that it may be an effective anxiolytic/antidepressant agent.	flesinoxan	25-35	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
8597527-3	1995	Flesinoxan (7 and 14 micrograms/kg), administered intravenously in 11 healthy volunteers, elicited a dose-related decrease in body temperature and increases in growth hormone, adrenocorticotropic hormone (ACTH), cortisol, and prolactin plasma levels.	flesinoxan	0-10	growth hormone 1	Homo sapiens	160-174
8597527-3	1995	Flesinoxan (7 and 14 micrograms/kg), administered intravenously in 11 healthy volunteers, elicited a dose-related decrease in body temperature and increases in growth hormone, adrenocorticotropic hormone (ACTH), cortisol, and prolactin plasma levels.	flesinoxan	0-10	proopiomelanocortin	Homo sapiens	176-203
8597527-3	1995	Flesinoxan (7 and 14 micrograms/kg), administered intravenously in 11 healthy volunteers, elicited a dose-related decrease in body temperature and increases in growth hormone, adrenocorticotropic hormone (ACTH), cortisol, and prolactin plasma levels.	flesinoxan	0-10	proopiomelanocortin	Homo sapiens	205-209
8597527-5	1995	The growth hormone response to flesinoxan was blocked by pindolol but not by methysergide, whereas the prolactin response was blocked by methysergide but not by pindolol.	flesinoxan	31-41	growth hormone 1	Homo sapiens	4-18
8597527-6	1995	The ACTH and cortisol responses to flesinoxan were potentiated by methysergide.	flesinoxan	35-45	proopiomelanocortin	Homo sapiens	4-8
8597527-8	1995	The present results suggest that the growth hormone response and the hypothermic response to the intravenous infusion of flesinoxan may serve as a valid index of 5-HT1A receptor function in humans.	flesinoxan	121-131	5-hydroxytryptamine receptor 1A	Homo sapiens	162-177
8614706-0	1995	The flesinoxan 5-HT1A receptor challenge in major depression and suicidal behavior.	flesinoxan	4-14	5-hydroxytryptamine receptor 1A	Homo sapiens	15-30
8614706-2	1995	In this study, we assessed the cortisol, ACTH, GH, prolactin and temperature responses to flesinoxan, a5-HT1A agonist, in 30 DSM-III-R major depressed inpatients subgrouped into suicide attempters (n = 15) and nonattempters (n = 15).	flesinoxan	90-100	5-hydroxytryptamine receptor 1A	Homo sapiens	103-109
7667330-6	1995	Further, a correlation analysis across each of the above agonists, as well as 8-OH-DPAT, buspirone, and (+)-flesinoxan, revealed a significant correlation for their relative potency in augmenting punished responding and their affinity for 5-HT1A receptors in vitro (r = +0.95, p < 0.001).	flesinoxan	104-118	5-hydroxytryptamine receptor 1A	Homo sapiens	239-245
7589185-0	1995	The anxiolytic effects of flesinoxan, a 5-HT1A receptor agonist, are not related to its neuroendocrine effects.	flesinoxan	26-36	5-hydroxytryptamine receptor 1A	Homo sapiens	40-55
7589185-3	1995	Under non-stress conditions, injection of 3 mg/kg flesinoxan significantly enhanced plasma corticosterone and glucose levels, whereas prolactin secretion was significantly enhanced after both 1 mg/kg and 3 mg/kg flesinoxan.	flesinoxan	212-222	prolactin	Homo sapiens	134-143
7589185-5	1995	The enhanced plasma prolactin levels induced by flesinoxan were not further affected by shock-probe exposure.	flesinoxan	48-58	prolactin	Homo sapiens	20-29
7813585-0	1994	Are the cardiovascular effects and "5-HT syndrome" induced by MDL 73,975 and flesinoxan in the dog mediated by 5-HT1A receptors?	flesinoxan	77-87	5-hydroxytryptamine receptor 1A	Canis lupus familiaris	111-117
7713161-1	1995	We tried to antagonize the endocrine and behavioural changes induced by the selective 5-HT1A receptor agonist, flesinoxan, with the putative 5-HT1A receptor antagonist, (S)-UH301 ((S)-5-fluoro-8-hydroxy-2-(di-n-propylamino)tetralin).	flesinoxan	111-121	5-hydroxytryptamine receptor 1A	Homo sapiens	86-101
7713161-5	1995	Moreover, flesinoxan-induced hyperglycemia and behavioural changes were effectively antagonized by (S)-UH301, showing potent 5-HT1A receptor antagonistic effects of (S)-UH301.	flesinoxan	10-20	5-hydroxytryptamine receptor 1A	Homo sapiens	125-140
7756102-12	1995	Only 10 mg DU 29894 and 1 mg flesinoxan produced statistically significant increases in ACTH, cortisol and growth hormone.	flesinoxan	29-39	proopiomelanocortin	Homo sapiens	88-92
22297764-2	1995	The 5-HT(1A) receptor full agonist flesinoxan (0.3-3.0 mg/kg) dose- and delay-dependently impaired performance, indicating a specific effect on WM.	flesinoxan	35-45	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-11
7813585-8	1994	In conclusion, MDL 73,975 and flesinoxan induced a 5-HT1A receptor-mediated fall in blood pressure but the changes in heart rate, respiratory rate and the "5-HT syndrome" are probably mediated by alpha 1-adrenoceptors.	flesinoxan	30-40	5-hydroxytryptamine receptor 1A	Canis lupus familiaris	51-66
7528302-5	1994	In 8 healthy volunteers, we infused 5-HT (0.1, 0.3, and 1 ng/kg/min) and the selective 5-HT1A receptor agonist flesinoxan (15, 45, and 150 ng/kg/min) intraarterially (i.a.)	flesinoxan	111-121	5-hydroxytryptamine receptor 1A	Homo sapiens	87-102
7969811-2	1994	Selective 5-HT1A agonists, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), flesinoxan, buspirone and ipsapirone significantly decreased the power value of 7-9 Hz band activity and the median frequency of wr-RSA.	flesinoxan	79-89	5-hydroxytryptamine receptor 1A	Rattus norvegicus	10-16
7972301-0	1994	Antianxiety and behavioral suppressant actions of the novel 5-HT1A receptor agonist, flesinoxan.	flesinoxan	85-95	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	60-75
7972301-1	1994	Flesinoxan is a potent and selective 5-HT1A receptor agonist.	flesinoxan	0-10	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	37-52
8012713-12	1994	It is concluded that the hypotensive agents flesinoxan and 5-methyl-urapidil appear to have different efficacies at 5-HT1A receptors located in different regions of the rodent brain.	flesinoxan	44-54	5-hydroxytryptamine receptor 1A	Rattus norvegicus	116-122
7909555-6	1994	Nevertheless, (+)-flesinoxan and LY 165,163 mimicked 8-OH-DPAT and WY 48,723 in eliciting a pronounced rise in plasma corticosterone and a marked hypothermia: these actions were blocked by the 5-HT1A receptor antagonist, (-)-alprenolol, but they were not affected by the alpha 1-antagonist prazosin.	flesinoxan	14-28	5-hydroxytryptamine receptor 1A	Rattus norvegicus	193-199
7909555-11	1994	STFs elicited by (+)-flesinoxan and LY 165,163 in the presence of cirazoline or ST 587 were blocked not only by prazosin but also by (-)-alprenolol, BMY 7378 and S 15535, all of which are antagonists of postsynaptic 5-HT1A receptors.	flesinoxan	17-31	5-hydroxytryptamine receptor 1A	Rattus norvegicus	216-222
7909555-13	1994	In conclusion, in the STF paradigm, the high-efficacy agonist actions of (+)-flesinoxan and LY 165,163 at 5-HT1A receptors are "masked" by their "intrinsic" alpha 1A-antagonist properties, the neutralization of which by alpha 1-agonists reveals the activation of 5-HT1A receptors.	flesinoxan	73-87	5-hydroxytryptamine receptor 1A	Rattus norvegicus	106-112
7909555-13	1994	In conclusion, in the STF paradigm, the high-efficacy agonist actions of (+)-flesinoxan and LY 165,163 at 5-HT1A receptors are "masked" by their "intrinsic" alpha 1A-antagonist properties, the neutralization of which by alpha 1-agonists reveals the activation of 5-HT1A receptors.	flesinoxan	73-87	5-hydroxytryptamine receptor 1A	Rattus norvegicus	263-269
8029269-8	1994	The present results are in agreement with previous findings concerning the stimulus effect of flesinoxan and point to a mechanism that involves the activation of 5-HT1A receptors in the brain.	flesinoxan	94-104	5-hydroxytryptamine receptor 1A	Rattus norvegicus	162-168
8263314-0	1993	An open study of oral flesinoxan, a 5-HT1A receptor agonist, in treatment-resistant depression.	flesinoxan	22-32	5-hydroxytryptamine receptor 1A	Homo sapiens	36-51
8263314-1	1993	Flesinoxan, a full 5-HT1A receptor agonist, was administered (4-8 mg) to treatment-resistant depressed patients in an open study.	flesinoxan	0-10	5-hydroxytryptamine receptor 1A	Homo sapiens	19-34
8012713-6	1994	The hypotensive drug flesinoxan, a selective 5-HT1A receptor agonist, hyperpolarized neurones in all three areas tested; however, another hypotensive agent with high affinity at 5-HT1A-receptors, 5-methyl-urapidil, hyperpolarized only the neurones in rat hippocampus and septum.	flesinoxan	21-31	5-hydroxytryptamine receptor 1A	Rattus norvegicus	45-51
8012713-6	1994	The hypotensive drug flesinoxan, a selective 5-HT1A receptor agonist, hyperpolarized neurones in all three areas tested; however, another hypotensive agent with high affinity at 5-HT1A-receptors, 5-methyl-urapidil, hyperpolarized only the neurones in rat hippocampus and septum.	flesinoxan	21-31	5-hydroxytryptamine receptor 1A	Rattus norvegicus	178-184
11224195-4	1993	Drugs with affinity for 5-HT(1A) receptors (i.e. 8-OHDPAT, flesinoxan, ipsapirone, buspirone, gepirone, NAN-190) abolished the vocalization irrespective of their efficacy.	flesinoxan	59-69	5-hydroxytryptamine receptor 1A	Rattus norvegicus	24-31
7906241-22	1993	These results show that the 5-HT1A receptor agonists 8-OH-DPAT, flesinoxan, 5-methyl-urapidil and MDL 75,608A show antihypertensive properties in conscious SHR after iv or icv injection.	flesinoxan	64-74	5-hydroxytryptamine receptor 1A	Rattus norvegicus	28-34
8382063-4	1993	Full inhibition was observed with 5-HT1A receptor agonists: N,N-dipropyl-8-hydroxy-2-aminotetralin (8-OH-DPAT) and flesinoxan, and non-selective 5-HT receptor agonists: d-lysergic acid diethylamide (d-LSD), RU 24,969, bufotenine, methysergide and tryptamine.	flesinoxan	115-125	5-hydroxytryptamine receptor 1A	Homo sapiens	34-49
7906241-23	1993	However, the mechanism of action of the compounds differs: 8-OH-DPAT and flesinoxan may act predominantly as 5-HT1A receptor agonists, where as 5-methyl-urapidil and MDL 75,608A also seem to have an effect on peripheral alpha 1-adrenoceptors.	flesinoxan	73-83	5-hydroxytryptamine receptor 1A	Rattus norvegicus	109-115
1532031-6	1992	The eltoprazine cue partially generalized to the cues of the 5-HT1a agonists flesinoxan and buspirone, (m-CPP), the 5-HT1b/1c agonist 1,3-chlorophenyl-piperazine dihydrochloride and the 5-HT1c/2 antagonist mesulergine, and did not generalize to the 5-HT2/1c agonist DOI.	flesinoxan	77-87	5-hydroxytryptamine receptor 1A	Rattus norvegicus	61-67
1352778-4	1992	Urapidil and 5-methyl-urapidil were less effective in decreasing arterial blood pressure than the lowest dose of the selective 5-HT1A receptor agonist, flesinoxan.	flesinoxan	152-162	5-hydroxytryptamine receptor 1A	Canis lupus familiaris	127-142
1352778-9	1992	Stimulation of 5-HT1A receptors alone, which is assumed to occur with flesinoxan, exerted antihypertensive activity only at low doses, without inducing reflex tachycardia at rest.	flesinoxan	70-80	5-hydroxytryptamine receptor 1A	Canis lupus familiaris	15-21
2142096-6	1990	The cardiovascular responses to flesinoxan and 8-OH-DPAT in the anaesthetized Wistar were inhibited by the putative 5-HT1A antagonists methiothepin, buspirone, spiroxatrine and 8-MeO-C1EPAT (8-methoxy-2-(N-2-cholroethyl-N-n-propylamino)tetralin).	flesinoxan	32-42	5-hydroxytryptamine receptor 1A	Rattus norvegicus	116-122
1786795-2	1991	Previous studies on anaesthetized animals indicate that flesinoxan exerts hypotensive effects via stimulation of central 5-HT1A receptors.	flesinoxan	56-66	5-hydroxytryptamine receptor 1A	Canis lupus familiaris	121-127
1675216-11	1991	During exercise both 5HT1A receptor agonists, flesinoxan and 8-OH-DPAT, decreased sympathetic tone.	flesinoxan	46-56	5-hydroxytryptamine receptor 1A	Canis lupus familiaris	21-35
1675216-14	1991	Stimulation of 5-HT1A receptors alone (flesinoxan) suppresses reflex tachycardia by modulation of baroreceptor reflex and at high dose also diminishes exercise-induced increase in sympathetic tone.	flesinoxan	39-49	5-hydroxytryptamine receptor 1A	Canis lupus familiaris	15-21
7870899-3	1993	5-HT1A agonists (BAY R 1531, 8-OHDPAT, flesinoxan, gepirone, 5MeO DMT, buspirone, ipsapirone, BMY 14802) completely inhibit the aggressive behaviour irrespective of their intrinsic activities.	flesinoxan	39-49	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	0-6
1351303-5	1992	Treatment with the 5-HT1A agonist flesinoxan (0.1-3.0 mg/kg) also dose-dependently decreased response rates while at the same time increasing reinforcement rates.	flesinoxan	34-44	5-hydroxytryptamine receptor 1A	Homo sapiens	19-25
1819150-6	1991	In contrast, the selective 5-HT1A receptor agonists 8-OH-DPAT and flesinoxan decrease blood pressure and heart rate by a centrally-mediated decrease in sympathetic tone and an increase in vagal tone.	flesinoxan	66-76	5-hydroxytryptamine receptor 1A	Homo sapiens	27-42
1673069-9	1991	Microinjections of the non-selective 5-HT1A receptor antagonists, (+/-)-pindolol (2.7 nmol) or methiothepin (5.2 nmol), into the raphe obscurus prevented the increase in blood pressure caused by microinjection of flesinoxan.	flesinoxan	213-223	5-hydroxytryptamine receptor 1A	Rattus norvegicus	37-43
2142096-10	1990	This study confirms the involvement of central 5-HT1A receptors in the cardiovascular effects of flesinoxan and 8-OH-DPAT.	flesinoxan	97-107	5-hydroxytryptamine receptor 1A	Rattus norvegicus	47-53
2366880-2	1990	We investigated the hypotensive activity of flesinoxan (0.1 + 0.2 + 0.7 mumol/kg), a 5-HT1A-receptor agonist, in dogs anaesthetized with either morphine and pentobarbital or enflurane and also in the conscious state.	flesinoxan	44-54	5-hydroxytryptamine receptor 1A	Canis lupus familiaris	85-100
2140607-6	1990	These results, coupled with the finding that flesinoxan has a significant affinity and selectivity for 5-HT1A binding sites, suggest that the stimulus effects of flesinoxan are mediated by a 5-HT1A mechanism.	flesinoxan	45-55	5-hydroxytryptamine receptor 1A	Rattus norvegicus	103-109
2140607-6	1990	These results, coupled with the finding that flesinoxan has a significant affinity and selectivity for 5-HT1A binding sites, suggest that the stimulus effects of flesinoxan are mediated by a 5-HT1A mechanism.	flesinoxan	45-55	5-hydroxytryptamine receptor 1A	Rattus norvegicus	191-197
2140607-6	1990	These results, coupled with the finding that flesinoxan has a significant affinity and selectivity for 5-HT1A binding sites, suggest that the stimulus effects of flesinoxan are mediated by a 5-HT1A mechanism.	flesinoxan	162-172	5-hydroxytryptamine receptor 1A	Rattus norvegicus	103-109
2140607-6	1990	These results, coupled with the finding that flesinoxan has a significant affinity and selectivity for 5-HT1A binding sites, suggest that the stimulus effects of flesinoxan are mediated by a 5-HT1A mechanism.	flesinoxan	162-172	5-hydroxytryptamine receptor 1A	Rattus norvegicus	191-197
2234097-2	1990	The 5-HT1A ligand flesinoxan produced inhibition of contractions which was not inhibited by cyanopindolol or yohimbine.	flesinoxan	18-28	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
22156500-5	1989	In a second study flesinoxan substituted for the 5-HT(1A) anxiolytic buspirone under a drug discrimination procedure, providing further evidence that the behavioural effects offlesinoxan are mediated by 5-HT(1A) mechanisms.	flesinoxan	18-28	5-hydroxytryptamine receptor 1A	Homo sapiens	203-210
35245487-3	2022	Moreover, this emotional abnormality was alleviated by chronic treatment with flesinoxan, a serotonin (5-HT)1A receptor agonist.	flesinoxan	78-88	coiled-coil and C2 domain containing 1A	Mus musculus	103-119
2481192-0	1989	Systemic and regional hemodynamic effects of the putative 5-HT1A receptor agonist flesinoxan in the cat.	flesinoxan	82-92	5-hydroxytryptamine receptor 1A	Homo sapiens	58-73
2481192-1	1989	The systemic and regional hemodynamic effects of the centrally acting putative 5-HT1A receptor agonist flesinoxan (3, 10, 30, and 100 micrograms/kg) were investigated in the anesthetized cat and compared with those of 8-hydroxy-2(di-n-prophylamino) tetralin (8-OH-DPAT 3, 10, 30, and 100 micrograms/kg) and clonidine (0.3, 1, 3, and 10 micrograms/kg).	flesinoxan	103-113	5-hydroxytryptamine receptor 1A	Homo sapiens	79-94
2481192-10	1989	These results establish that the 5-HT1A receptor agonists flesinoxan and 8-OH-DPAT elicited a systemic and regional hemodynamic profile that differs from that of the alpha 2-adrenoceptor agonist clonidine.	flesinoxan	58-68	5-hydroxytryptamine receptor 1A	Homo sapiens	33-48
34673172-1	2021	We previously reported that abnormal emotionality in stress-maladaptive mice was ameliorated by chronic treatment with flesinoxan, a 5-HT1A receptor agonist.	flesinoxan	119-129	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	133-148
23916504-10	2014	Flesinoxan had a MED <=1.0mg/kg (~25% 5-HT1A receptor occupancy; SA); only 1.0mg/kg ameliorated deficits in the NOR.	flesinoxan	0-10	5-hydroxytryptamine receptor 1A	Rattus norvegicus	41-47
22156500-0	1989	Anticonflict effects of the 5-HT1A compound flesinoxan.	flesinoxan	44-54	5-hydroxytryptamine receptor 1A	Homo sapiens	28-34
22156500-1	1989	The new phenylpiperazine derivative flesinoxan, a potent and selective serotonin(1A) (5-HT(1A)) agonist, was examined under a procedure that has proved to be a reliable and sensitive method for detecting novel anxiolytic drugs believed to produce their effects at the 5-HT( 1A) receptor subtype.	flesinoxan	36-46	5-hydroxytryptamine receptor 1A	Homo sapiens	86-93
22156500-1	1989	The new phenylpiperazine derivative flesinoxan, a potent and selective serotonin(1A) (5-HT(1A)) agonist, was examined under a procedure that has proved to be a reliable and sensitive method for detecting novel anxiolytic drugs believed to produce their effects at the 5-HT( 1A) receptor subtype.	flesinoxan	36-46	5-hydroxytryptamine receptor 1A	Homo sapiens	268-286
25233810-4	2016	The combination of spadin with the 5-HT4 agonist RS 67333 paradoxically reduced 5-HT firing, an effect reversed by acutely administering the 5-HT1A agonist flesinoxan.	flesinoxan	156-166	5-hydroxytryptamine receptor 1A	Homo sapiens	141-147
21487650-9	2011	Finally, the hypothermic response to the 5-HT(1A) agonist flesinoxan was observed at a lower dose in prenatally fluoxetine-exposed rats than in controls.	flesinoxan	58-68	5-hydroxytryptamine receptor 1A	Rattus norvegicus	41-48
21723276-6	2011	The stress-reducing effect of the 5-HT(1A) receptor agonist flesinoxan on increases in body temperature, heart rate and locomotor activity was similar in wild type and 5-HT(1B) knockout mice before and after chronic 21-day treatment with the SSRI fluvoxamine, indicating no apparent alteration of 5-HT(1A) receptor sensitivity in 5-HT(1B) knockout mice.	flesinoxan	60-70	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	34-51
18786747-4	2008	5-HT(1A) receptor sensitivity following chronic administration of the SSRI paroxetine was assessed by the ability of an acute challenge with the 5-HT(1A) agonist, flesinoxan, to modulate 5-HT synthesis in the rat brain.	flesinoxan	163-173	5-hydroxytryptamine receptor 1A	Rattus norvegicus	0-7
18786747-4	2008	5-HT(1A) receptor sensitivity following chronic administration of the SSRI paroxetine was assessed by the ability of an acute challenge with the 5-HT(1A) agonist, flesinoxan, to modulate 5-HT synthesis in the rat brain.	flesinoxan	163-173	5-hydroxytryptamine receptor 1A	Rattus norvegicus	145-152
18606402-10	2008	The flesinoxan-induced hypothermia in SERT(+/+) rats was blocked by the 5-HT(1A) receptor antagonist [N-(2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl)-N-(2-pyridinyl) cyclohexane carboxamide 3HCl (WAY100635).	flesinoxan	4-14	solute carrier family 6 member 4	Rattus norvegicus	38-42
17574706-2	2007	In this study, we used the alpha-[(14)C]methyl-l-tryptophan (alpha-MTrp) autoradiographic method to evaluate the effects of the 5-HT(1A) agonist, flesinoxan, on regional 5-HT synthesis in the rat brain, following acute or a 14-day continuous treatment.	flesinoxan	146-156	5-hydroxytryptamine receptor 1A	Rattus norvegicus	128-135
17574706-10	2007	The unaltered 5-HT synthesis rates in a large majority of regions following the 14-day treatment of flesinoxan may reflect the normalization (implies to not be different from salne treated control) of synthesis due to a desensitization of 5-HT(1A) autoreceptors on the cell body of 5-HT neurons as well as at postsynaptic sites, which is known to occur following long-term treatment with 5-HT(1A) agonists.	flesinoxan	100-110	5-hydroxytryptamine receptor 1A	Rattus norvegicus	239-246
17574706-10	2007	The unaltered 5-HT synthesis rates in a large majority of regions following the 14-day treatment of flesinoxan may reflect the normalization (implies to not be different from salne treated control) of synthesis due to a desensitization of 5-HT(1A) autoreceptors on the cell body of 5-HT neurons as well as at postsynaptic sites, which is known to occur following long-term treatment with 5-HT(1A) agonists.	flesinoxan	100-110	5-hydroxytryptamine receptor 1A	Rattus norvegicus	388-395